Diversity of envelope genes from an uncloned stock of SIVmac251

Jacqueline G. Bixby, Olga Laur, Welkin E. Johnson, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

AIDS vaccine and pathogenesis research will benefit from a more diverse array of cloned SIV challenge stocks from which to choose. Toward this end, 20 envelope genes were cloned from an extensively used, primary stock of uncloned SIVmac251. Each of the 20 clones had a unique sequence. Their translated sequences differed by as many as 26 amino acids from one another and by as many as 45 amino acids from the commonly used clone SIVmac239. Envelope sequences up to and including the membrane-spanning domain were exchanged into the infectious pathogenic SIVmac239 clone and virus stocks were produced by HEK293T cell transfection. Seventeen of the 20 recombinants were replication competent. The infectivities per ng p27 of the 17 new replication-competent recombinants in C8166-SEAP cells and in TZM-bl cells ranged from minus 32-fold to plus 7.6-fold relative to SIVmac239. A range of sensitivities to neutralization by sCD4 and by sera from SIV-infected macaques was observed but none was as sensitive to these neutralizing agents as SIVmac316, the highly macrophage-competent derivative of SIVmac239. Four strains that were most sensitive to sCD4 inhibition were also among the most sensitive to antibody-mediated neutralization. None of the new recombinant viruses replicated as well as SIVmac316 in primary alveolar macrophage cultures from rhesus monkeys but three of the strains did exhibit significant levels of delayed replication in these primary macrophages, reaching peak levels of virus production of ≥50 ng/ml p27 compared to 600-800 ng/ml p27 with SIVmac316. These new SIV clones are being contributed to the NIH AIDS Reagent Repository and are available to the scientific community.

Original languageEnglish (US)
Pages (from-to)1115-1131
Number of pages17
JournalAIDS Research and Human Retroviruses
Volume26
Issue number10
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Clone Cells
Viruses
Genes
Macrophages
Amino Acids
AIDS Vaccines
Alveolar Macrophages
Macaca
Macaca mulatta
Transfection
Acquired Immunodeficiency Syndrome
Membranes
Antibodies
Serum
Research

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Diversity of envelope genes from an uncloned stock of SIVmac251. / Bixby, Jacqueline G.; Laur, Olga; Johnson, Welkin E.; Desrosiers, Ronald Charles.

In: AIDS Research and Human Retroviruses, Vol. 26, No. 10, 01.10.2010, p. 1115-1131.

Research output: Contribution to journalArticle

Bixby, Jacqueline G. ; Laur, Olga ; Johnson, Welkin E. ; Desrosiers, Ronald Charles. / Diversity of envelope genes from an uncloned stock of SIVmac251. In: AIDS Research and Human Retroviruses. 2010 ; Vol. 26, No. 10. pp. 1115-1131.
@article{96c3eb49e62c491190c21e39a878d897,
title = "Diversity of envelope genes from an uncloned stock of SIVmac251",
abstract = "AIDS vaccine and pathogenesis research will benefit from a more diverse array of cloned SIV challenge stocks from which to choose. Toward this end, 20 envelope genes were cloned from an extensively used, primary stock of uncloned SIVmac251. Each of the 20 clones had a unique sequence. Their translated sequences differed by as many as 26 amino acids from one another and by as many as 45 amino acids from the commonly used clone SIVmac239. Envelope sequences up to and including the membrane-spanning domain were exchanged into the infectious pathogenic SIVmac239 clone and virus stocks were produced by HEK293T cell transfection. Seventeen of the 20 recombinants were replication competent. The infectivities per ng p27 of the 17 new replication-competent recombinants in C8166-SEAP cells and in TZM-bl cells ranged from minus 32-fold to plus 7.6-fold relative to SIVmac239. A range of sensitivities to neutralization by sCD4 and by sera from SIV-infected macaques was observed but none was as sensitive to these neutralizing agents as SIVmac316, the highly macrophage-competent derivative of SIVmac239. Four strains that were most sensitive to sCD4 inhibition were also among the most sensitive to antibody-mediated neutralization. None of the new recombinant viruses replicated as well as SIVmac316 in primary alveolar macrophage cultures from rhesus monkeys but three of the strains did exhibit significant levels of delayed replication in these primary macrophages, reaching peak levels of virus production of ≥50 ng/ml p27 compared to 600-800 ng/ml p27 with SIVmac316. These new SIV clones are being contributed to the NIH AIDS Reagent Repository and are available to the scientific community.",
author = "Bixby, {Jacqueline G.} and Olga Laur and Johnson, {Welkin E.} and Desrosiers, {Ronald Charles}",
year = "2010",
month = "10",
day = "1",
doi = "10.1089/aid.2010.0029",
language = "English (US)",
volume = "26",
pages = "1115--1131",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Diversity of envelope genes from an uncloned stock of SIVmac251

AU - Bixby, Jacqueline G.

AU - Laur, Olga

AU - Johnson, Welkin E.

AU - Desrosiers, Ronald Charles

PY - 2010/10/1

Y1 - 2010/10/1

N2 - AIDS vaccine and pathogenesis research will benefit from a more diverse array of cloned SIV challenge stocks from which to choose. Toward this end, 20 envelope genes were cloned from an extensively used, primary stock of uncloned SIVmac251. Each of the 20 clones had a unique sequence. Their translated sequences differed by as many as 26 amino acids from one another and by as many as 45 amino acids from the commonly used clone SIVmac239. Envelope sequences up to and including the membrane-spanning domain were exchanged into the infectious pathogenic SIVmac239 clone and virus stocks were produced by HEK293T cell transfection. Seventeen of the 20 recombinants were replication competent. The infectivities per ng p27 of the 17 new replication-competent recombinants in C8166-SEAP cells and in TZM-bl cells ranged from minus 32-fold to plus 7.6-fold relative to SIVmac239. A range of sensitivities to neutralization by sCD4 and by sera from SIV-infected macaques was observed but none was as sensitive to these neutralizing agents as SIVmac316, the highly macrophage-competent derivative of SIVmac239. Four strains that were most sensitive to sCD4 inhibition were also among the most sensitive to antibody-mediated neutralization. None of the new recombinant viruses replicated as well as SIVmac316 in primary alveolar macrophage cultures from rhesus monkeys but three of the strains did exhibit significant levels of delayed replication in these primary macrophages, reaching peak levels of virus production of ≥50 ng/ml p27 compared to 600-800 ng/ml p27 with SIVmac316. These new SIV clones are being contributed to the NIH AIDS Reagent Repository and are available to the scientific community.

AB - AIDS vaccine and pathogenesis research will benefit from a more diverse array of cloned SIV challenge stocks from which to choose. Toward this end, 20 envelope genes were cloned from an extensively used, primary stock of uncloned SIVmac251. Each of the 20 clones had a unique sequence. Their translated sequences differed by as many as 26 amino acids from one another and by as many as 45 amino acids from the commonly used clone SIVmac239. Envelope sequences up to and including the membrane-spanning domain were exchanged into the infectious pathogenic SIVmac239 clone and virus stocks were produced by HEK293T cell transfection. Seventeen of the 20 recombinants were replication competent. The infectivities per ng p27 of the 17 new replication-competent recombinants in C8166-SEAP cells and in TZM-bl cells ranged from minus 32-fold to plus 7.6-fold relative to SIVmac239. A range of sensitivities to neutralization by sCD4 and by sera from SIV-infected macaques was observed but none was as sensitive to these neutralizing agents as SIVmac316, the highly macrophage-competent derivative of SIVmac239. Four strains that were most sensitive to sCD4 inhibition were also among the most sensitive to antibody-mediated neutralization. None of the new recombinant viruses replicated as well as SIVmac316 in primary alveolar macrophage cultures from rhesus monkeys but three of the strains did exhibit significant levels of delayed replication in these primary macrophages, reaching peak levels of virus production of ≥50 ng/ml p27 compared to 600-800 ng/ml p27 with SIVmac316. These new SIV clones are being contributed to the NIH AIDS Reagent Repository and are available to the scientific community.

UR - http://www.scopus.com/inward/record.url?scp=77958173058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958173058&partnerID=8YFLogxK

U2 - 10.1089/aid.2010.0029

DO - 10.1089/aid.2010.0029

M3 - Article

C2 - 20836705

AN - SCOPUS:77958173058

VL - 26

SP - 1115

EP - 1131

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 10

ER -